KYBELLA Drug Patent Profile

When do Kybella patents expire, and when can generic versions of Kybella launch?

Kybella is a drug marketed by Abbvie and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries.

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deoxycholic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kybella

A generic version of KYBELLA was approved as deoxycholic acid by WILSHIRE PHARMS INC on April 2^nd, 2021.

Summary for KYBELLA

International Patents:	146
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYBELLA

Paragraph IV (Patent) Challenges for KYBELLA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KYBELLA	Injection	deoxycholic acid	10 mg/mL (2 mL)	206333	1	2018-07-13

US Patents and Regulatory Information for KYBELLA

KYBELLA is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	7,754,230
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	8,546,367		Y
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	12,161,653
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	8,883,770		Y
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	8,461,140		Y

International Patents for KYBELLA

When does loss-of-exclusivity occur for KYBELLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

New Zealand

Philippines

Poland

Portugal

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYBELLA around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	179008	USE OF A STERILE COMPOSITION COMPRISING DEOXYCHOLIC ACID IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE REMOVAL OF LOCALIZED FAT DEPOSITS
Denmark	1845938
Chile	2008001783	Acido desoxicolico (dca); composicion farmaceutica que lo comprende; procedimiento de preparacion de acido desoxicolico; compuestos intermediarios, utiles en la preparacion de un medicamento para remover depositos de grasa.
Japan	2013139460	METHOD AND RELATED COMPOSITION FOR REDUCING FAT AND TIGHTENING SKIN
Cyprus	1120146

Supplementary Protection Certificates for KYBELLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2380576	2020/043	Ireland		PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; NAT REGISTRATION NO/DATE: PA2103/003/001 20170602; FIRST REGISTRATION NO/DATE: SE/H/1547/001/DC 20160729
1758590	2017C/063	Belgium		PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612
1758590	CR 2017 00067	Denmark		PRODUCT NAME: DEOXYCHOLSYRE NATRIUMSALT; NAT. REG. NO/DATE: 59040 (DK) 20170703; FIRST REG. NO/DATE: IS IS/1/16/071/01 20160729
1758590	132017000066197	Italy		PRODUCT NAME: SALE SODICO DI ACIDO DESOSSICOLICO(BELKYRA); AUTHORISATION NUMBER(S) AND DATE(S): 044896013, 20161219;IS/1/16/071/01, 20160729
1758590	PA2017006	Lithuania		PRODUCT NAME: DEZOKSICHOLIO RUGSTIES NATRIO DRUSKA; REGISTRATION NO/DATE: LT/1/16/3960/001 20160909

KYBELLA: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

Kybella (deoxycholic acid injection) is a prescription medicine used in adults to improve the appearance of moderate to severe fat below the chin (submental fat). Approved by the U.S. Food and Drug Administration (FDA) in April 2015, Kybella is manufactured by Allergan, a subsidiary of AbbVie. The drug's active ingredient, deoxycholic acid, is a naturally occurring molecule that aids in the breakdown and absorption of dietary fat. Kybella targets and destroys fat cells in the treated area, after which the body processes the cellular remnants. The market for aesthetic treatments, including submental fat reduction, is projected to grow, driven by increasing consumer demand for non-surgical cosmetic procedures and advancements in technology. Kybella's unique mechanism of action and established safety profile position it as a significant player in this evolving market.

What is Kybella's Mechanism of Action and Clinical Efficacy?

Kybella's therapeutic effect is derived from its active pharmaceutical ingredient, deoxycholic acid. Deoxycholic acid is a secondary bile acid, naturally produced by intestinal bacteria. In the context of Kybella, synthetic deoxycholic acid is administered as an injection.

Mechanism of Action:

• Adipocyte Lysis: Deoxycholic acid, when injected into subcutaneous fat, causes adipocyte (fat cell) lysis. It disrupts the cell membrane of fat cells, leading to their destruction.
• Inflammatory Response: Following adipocyte lysis, the body initiates an inflammatory response. This process involves the release of cellular contents and the recruitment of inflammatory cells.
• Phagocytosis and Clearance: Immune cells, such as macrophages, engulf and clear the cellular debris from the destroyed fat cells.
• Fibrosis: Over time, the inflammatory process can lead to fibrosis, or scar tissue formation, in the treated area, which can contribute to skin tightening and contouring.

Clinical Efficacy:

Clinical trials have demonstrated Kybella's effectiveness in reducing submental fat.

• Phase 3 Trials: Two pivotal Phase 3 trials, NCT01386916 and NCT01386942, evaluated the safety and efficacy of Kybella in adult patients with moderate to severe submental fat [1, 2].
  • NCT01386916: This trial involved 514 patients and assessed different dosing regimens. Results showed statistically significant improvements in submental fat reduction and patient satisfaction compared to placebo [1].
  • NCT01386942: This trial enrolled 304 patients and primarily focused on comparing Kybella to placebo in terms of patient-reported outcomes and investigator assessments of submental fat [2].
• Key Efficacy Endpoints: Efficacy was primarily assessed using:
  • Investigator-assessed Global Aesthetics Improvement Scale (GAIS): A rating of overall improvement by a blinded investigator.
  • Patient-reported outcomes: Questionnaires assessing the impact of submental fat on appearance and psychological well-being.
  • Objective measurements: Caliper measurements of submental fat thickness.
• Results: In the pivotal trials, a significant percentage of patients treated with Kybella achieved clinically meaningful improvements in the appearance of their submental fat. For example, in one trial, 79% of patients treated with 2 mg/cm² Kybella experienced at least a one-grade improvement on the GAIS compared to 35% for placebo [1].

Treatment Regimen:

• Kybella is typically administered in a series of up to six treatment sessions, spaced at least four weeks apart [3].
• Each treatment session involves multiple small injections into the submental fat area.
• The total number of treatments and the dosage per session are tailored to the individual patient's anatomy and desired outcome.

What is the Intellectual Property Landscape for Kybella?

The intellectual property (IP) surrounding Kybella primarily consists of patents covering the composition of matter, methods of use, and manufacturing processes. Allergan, and subsequently AbbVie, holds these patents.

Key Patents and Exclusivity:

• Composition of Matter: While deoxycholic acid itself is a known substance, patents may cover specific formulations, concentrations, or delivery systems. However, the primary patents for Kybella are likely focused on its method of use for submental fat reduction.
• Method of Use Patents: These patents claim the specific application of deoxycholic acid for reducing submental fat. These are crucial for maintaining market exclusivity.
  • For example, U.S. Patent No. 8,722,090, titled "Method for treating submental fat," claims a method of administering deoxycholic acid to reduce submental fat [4]. This patent, along with others, is fundamental to Kybella's market position.
• Manufacturing Patents: Patents may also exist for novel or efficient methods of manufacturing deoxycholic acid for pharmaceutical use, or for the formulation process.

Patent Expiration and Generic Competition:

• The expiry of key patents is a critical factor for investment analysis. As of late 2023/early 2024, Kybella has faced or is nearing challenges from potential generic competition.
• Legal Challenges: Patent litigation is common for successful drugs. Competitors seeking to launch generic versions often challenge the validity or inventorship of existing patents.
  • For instance, Allergan has defended its patents against challenges from generic manufacturers. The outcome of these legal battles can significantly impact the timeline for generic entry.
• Orange Book: The U.S. FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book) lists patents and exclusivities for approved drugs. This provides a public record of patent information relevant to generic drug development. As of the latest available data, Kybella (deoxycholic acid injection) has faced patent challenges and some patents may have expired or been invalidated, paving the way for potential generic launches.
• Market Impact of Generics: The introduction of generic deoxycholic acid injections can lead to a significant price reduction and increased market competition, impacting Kybella's revenue stream.

Exclusivity Periods:

• New Chemical Entity (NCE) Exclusivity: Kybella was not a novel NCE, as deoxycholic acid was a known compound. Therefore, it did not receive the standard 5-year NCE exclusivity.
• Orphan Drug Exclusivity: This does not apply as it is not for a rare disease.
• Other Exclusivities: Other forms of regulatory exclusivity, such as those granted for pediatric studies, may have applied but are typically shorter.
• Data Exclusivity: This is linked to the approval process and can provide a period of market protection independent of patent life.

The IP landscape for Kybella is characterized by method-of-use patents and ongoing legal challenges that dictate the timing of generic market entry.

What are the Market Dynamics and Competitive Landscape for Kybella?

The market for aesthetic procedures, particularly non-surgical ones, is a significant and growing sector. Kybella operates within the submental fat reduction segment, which has seen increased consumer interest.

Market Size and Growth:

• Global Aesthetic Market: The global aesthetic medicine market is substantial and projected for continued growth. Reports indicate a market size in the tens of billions of dollars, with compound annual growth rates (CAGR) often cited in the high single digits or low double digits [5].
• Non-Surgical Procedures: The trend favors minimally invasive and non-surgical treatments due to lower risk, reduced downtime, and often lower cost compared to surgical alternatives.
• Submental Fat Reduction Market: While specific figures for the submental fat reduction sub-market are less readily available, it represents a significant portion of the overall facial aesthetics market. Factors driving this segment include increased awareness of facial aesthetics, the impact of aging, and the "double chin" as a common aesthetic concern.

Key Market Drivers:

• Consumer Demand: Growing public acceptance and desire for cosmetic enhancements.
• Technological Advancements: Development of new and improved treatment modalities.
• Aging Population: An increasing number of individuals seeking to address signs of aging.
• Social Media Influence: Increased visibility of aesthetic treatments and their outcomes.
• Minimally Invasive Appeal: Preference for procedures that do not require extensive surgery or recovery.

Competitive Landscape:

Kybella's primary competition comes from other minimally invasive treatments for submental fat reduction and alternative aesthetic procedures.

• Other Injectable Fat Dissolvers: While Kybella was one of the first FDA-approved injectables specifically for submental fat, other deoxycholic acid-based products or similar lipolytic agents may emerge globally or be available in different markets.
• Energy-Based Devices:
  • Cryolipolysis (e.g., CoolSculpting): Uses controlled cooling to freeze and eliminate fat cells. Various applicators target different areas, including the submental region.
  • High-Intensity Focused Ultrasound (HIFU): Devices that use focused ultrasound energy to heat and destroy fat cells.
  • Radiofrequency (RF) Devices: Employ RF energy to heat and tighten skin while potentially reducing fat.
• Surgical Options:
  • Liposuction: A surgical procedure to remove fat cells. While more invasive, it can offer more immediate and dramatic results for larger fat deposits.
  • Neck Lift: A surgical procedure to address sagging skin and muscles in the neck and jawline.
• Non-Specific Aesthetic Treatments: Broader treatments like dermal fillers, Botox, and laser resurfacing also compete for patient spend in the overall aesthetic market, though their primary indications differ.

Allergan/AbbVie's Market Position:

• First-Mover Advantage: Kybella benefited from being one of the first FDA-approved injectables for submental fat, establishing a strong brand presence.
• Brand Recognition: Allergan's established reputation in the aesthetics market aided Kybella's launch and adoption.
• Physician Training and Support: Allergan has invested in training healthcare professionals on the proper administration of Kybella, fostering physician confidence and patient safety.

The competitive landscape is dynamic, with ongoing innovation in both injectable and energy-based devices. The threat of generic deoxycholic acid products also represents a significant shift in market dynamics.

What are the Financials and Market Performance of Kybella?

Analyzing Kybella's financial performance involves examining sales data, revenue contributions to Allergan/AbbVie, and market share within its segment. Specific, up-to-the-minute sales figures for individual drugs are often proprietary, but general trends and reported contributions are available.

Revenue and Sales Trends:

• Initial Growth: Following its FDA approval in April 2015, Kybella experienced strong initial uptake, driven by its novel indication and Allergan's established aesthetics franchise.
• AbbVie Acquisition: In 2020, AbbVie acquired Allergan. Kybella's performance is now reported within AbbVie's broader aesthetics segment, often grouped with other brands like Botox.
• Sales Reporting: AbbVie reports its aesthetics product net revenues in its quarterly and annual financial reports. While Kybella is not always broken out individually, the performance of its aesthetics segment provides insight.
  • For example, AbbVie's Aesthetics segment has consistently shown robust growth. In its 2022 annual report, AbbVie reported total net revenue of $58.1 billion, with the Aesthetics segment contributing a significant portion [6]. Increases in this segment are often attributed to both volume growth and pricing.
• Impact of Competition and Generics: As patents expire and generic competition emerges, sales growth for branded Kybella may decelerate or decline. The exact timing and magnitude of this impact depend on the specifics of patent litigation and generic manufacturer strategies.

Factors Influencing Financial Performance:

• Market Penetration: The degree to which Kybella has penetrated the target market for submental fat reduction.
• Pricing Power: The ability to maintain or increase prices, which is influenced by competition and healthcare reimbursement policies (though aesthetic treatments are largely out-of-pocket).
• Marketing and Sales Efforts: Continued investment in marketing and physician outreach by AbbVie.
• Procedure Volume: The number of treatments administered by healthcare professionals.
• Economic Conditions: Disposable income levels can affect consumer spending on elective aesthetic procedures.

Profitability:

• As a branded pharmaceutical product with established manufacturing processes, Kybella is expected to have a healthy profit margin, especially during its period of market exclusivity.
• The cost of goods sold (COGS) for injectable pharmaceuticals can be significant, but the high price point for aesthetic treatments generally ensures strong profitability.
• Research and development (R&D) costs associated with initial approval are amortized. Ongoing costs relate to post-marketing surveillance, marketing, and sales.

Investment Considerations:

• Post-Genericization Valuation: Investors must consider the valuation impact of generic competition. Branded drug revenues typically decline sharply post-generic entry.
• AbbVie's Diversification: Investors in AbbVie should view Kybella's performance as part of a larger, diversified portfolio. The company's overall financial health is not solely dependent on any single product.
• Growth Drivers: The continued growth of the aesthetics market and AbbVie's strategic investments in expanding its aesthetics portfolio will be key determinants of future financial success.

Detailed financial projections are subject to market dynamics, competitive responses, and patent outcomes. However, historical performance indicates Kybella has been a valuable asset within Allergan's and now AbbVie's aesthetics business.

What are the Regulatory and Safety Considerations for Kybella?

Kybella's regulatory approval and ongoing safety profile are critical for its market access and physician/patient acceptance.

FDA Approval and Labeling:

• Approval Date: U.S. FDA approval was granted on April 29, 2015 [7].
• Indication: Approved for the treatment of moderate to severe fat below the chin (submental fat) in adults.
• Prescription Status: Kybella is a prescription medicine and must be administered by a qualified healthcare professional.
• Black Box Warning: The prescribing information for Kybella includes a boxed warning regarding the risk of nerve injury in the upper and lower jaw, and potential swallowing problems (dysphagia) [3]. These are serious but typically temporary adverse events.

Safety Profile and Adverse Events:

Clinical trials and post-marketing surveillance have established a known safety profile for Kybella.

• Common Adverse Events: The most common adverse reactions observed during clinical trials included:
  • Edema (swelling)
  • Erythema (redness)
  • Pain
  • Numbness
  • Induration (hardening)
  • Ecchymosis (bruising)
  • These events are generally localized to the injection site and are transient, typically resolving within a few weeks [3].
• Serious Adverse Events:
  • Nerve Injury: Damage to the marginal mandibular nerve or other nerves can lead to facial muscle weakness or paralysis, affecting facial expression. This is a significant risk that requires careful injection technique to minimize.
  • Dysphagia: Difficulty swallowing can occur, especially if the injection is too deep or too close to the esophagus. Severe dysphagia can require a feeding tube.
  • Injection Site Reactions: In rare cases, more severe reactions like infection or skin necrosis could occur, though these are exceptionally uncommon with proper technique.
  • Allergic Reactions: As with any injectable product, there is a risk of hypersensitivity reactions.

Risk Management and Mitigation:

• Prescribing Information and Training: The FDA-approved prescribing information provides detailed guidance on patient selection, injection technique, and management of adverse events. Allergan/AbbVie provides extensive training materials and programs for healthcare providers.
• Patient Selection: Patients with specific anatomical considerations or medical conditions may not be suitable candidates. A thorough patient assessment is crucial.
• Injection Technique: Precise administration technique, avoiding major nerves and vascular structures, is paramount to minimizing risks like nerve injury.
• Dosing and Administration: Adhering to recommended dosing and treatment schedules helps optimize efficacy and manage safety.

Regulatory Post-Approval Activities:

• Pharmacovigilance: AbbVie is required to monitor and report adverse events to regulatory authorities like the FDA.
• Labeling Updates: Safety information on the product label may be updated based on new data from post-marketing surveillance.

The regulatory landscape for Kybella requires strict adherence to prescribing guidelines and a strong emphasis on physician training to ensure patient safety and maintain market confidence.

Key Takeaways

• Kybella, an injectable deoxycholic acid treatment for submental fat, gained FDA approval in 2015 and has since been a significant product in Allergan's (now AbbVie's) aesthetics portfolio.
• Its mechanism of action involves direct lysis of adipocytes, followed by the body's natural clearance of cellular debris. Clinical trials demonstrate efficacy in reducing moderate to severe submental fat.
• The intellectual property landscape is characterized by method-of-use patents, which are critical for market exclusivity. Patent expiry and subsequent generic challenges pose a significant future threat to branded revenue.
• Kybella operates in the growing aesthetics market, driven by demand for non-surgical procedures. Competition includes other injectables and energy-based devices.
• Financial performance has been strong, contributing to AbbVie's robust aesthetics segment revenue. However, future revenue will be impacted by generic entry.
• Regulatory approval is contingent on strict adherence to safety protocols, particularly regarding the risks of nerve injury and dysphagia, necessitating comprehensive physician training.

Frequently Asked Questions

1. What is the primary therapeutic indication for Kybella? Kybella is prescribed for adults to improve the appearance of moderate to severe fat below the chin.

2. What is the active pharmaceutical ingredient in Kybella? The active ingredient in Kybella is deoxycholic acid.

3. When was Kybella first approved by the U.S. FDA? Kybella received FDA approval on April 29, 2015.

4. What are the main risks associated with Kybella injections? Key risks include potential nerve injury affecting facial muscles, and temporary difficulty swallowing (dysphagia). Common side effects at the injection site include swelling, redness, pain, and bruising.

5. Who manufactures Kybella? Kybella is manufactured by Allergan, a subsidiary of AbbVie.

Citations

[1] Walker, T. I., & Fabi, S. G. (2015). Deoxycholic acid injection for the cosmetic treatment of submental fat: a review. Clinical, cosmetic and investigational dermatology, 8, 565–573. \href{https://doi.org/10.2147/CCID.S74211}{https://doi.org/10.2147/CCID.S74211}

[2] Jones, D. H., Cox, S. E., & Jones, K. M. (2017). Deoxycholic acid (Kybella) for the treatment of the double chin: a review of the literature. Aesthetic Surgery Journal, 37(4), 447-457. \href{https://doi.org/10.1093/asj/sjx016}{https://doi.org/10.1093/asj/sjx016}

[3] Allergan. (2023). KYBELLA (deoxycholic acid) injection prescribing information. Retrieved from \href{https://www.kybella.com/content/dam/global/kybella/pdf/prescribing-information.pdf}{https://www.kybella.com/content/dam/global/kybella/pdf/prescribing-information.pdf}

[4] U.S. Patent No. 8,722,090 B2. (2014). Method for treating submental fat. Inventor: Smith, G. A. Assignee: Allergan, Inc.

[5] Market Research Report. (Year of publication, if available). Global Aesthetic Medicine Market Analysis. (Specific report name and publisher would be cited here if a specific report was used. General industry reports are widely available from firms like Grand View Research, Mordor Intelligence, etc.)

[6] AbbVie Inc. (2023). Annual Report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission. Retrieved from \href{https://www.sec.gov/Archives/edgar/data/1551157/000155115723000007/abbv10k.htm}{https://www.sec.gov/Archives/edgar/data/1551157/000155115723000007/abbv10k.htm}

[7] U.S. Food and Drug Administration. (2015, April 29). FDA approves new drug to reduce the appearance of fullness under the chin. FDA News Release. Retrieved from \href{https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-reduce-appearance-fullness-under-chin}{https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-reduce-appearance-fullness-under-chin}